Literature DB >> 12027898

Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity.

Julie Tabiasco1, Frédéric Pont, Jean-Jacques Fournié, Alain Vercellone.   

Abstract

Mistletoe extracts have immunomodulatory activity. We show that nontoxic concentrations of Viscum album extracts increase natural killer (NK) cell-mediated killing of tumor cells but spare nontarget cells from NK lysis. The compounds responsible for this bioactivity were isolated from mistletoe and characterized. They have low molecular mass and are thermostable and protease-resistant. After complete purification by HPLC, they were identified by tandem MS as viscotoxins A1, A2 and A3 (VTA1, VTA2 and VTA3, respectively). Whereas micromolar concentrations of these viscotoxins are cytotoxic to the targets, the bioactivity with respect to NK lysis is within the nanomolar range and differs between viscotoxin isoforms: VTA1 (85 nm), VTA2 (18 nm) and VTA3 (8 nm). Microphysiometry and assays of cell killing indicate that, within such nontoxic concentrations, viscotoxins do not activate NK cells, but act on cell conjugates to increase the resulting lysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027898     DOI: 10.1046/j.1432-1033.2002.02932.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.

Authors:  Gil Bar-Sela; Nissim Haim
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Interaction of viscotoxins A3 and B with membrane model systems: implications to their mechanism of action.

Authors:  Marcela Giudici; Roberto Pascual; Laura de la Canal; Karola Pfüller; Uwe Pfüller; José Villalaín
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

3.  Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Authors:  Soo Jung Lee; Young-Ok Son; Hyunjin Kim; Joo-Young Kim; Soon-Won Park; Jae-Ho Bae; Hyung Hoi Kim; Eun-Yup Lee; Byung-Seon Chung; Sun-Hee Kim; Chi-Dug Kang
Journal:  J Clin Immunol       Date:  2007-05-25       Impact factor: 8.317

Review 4.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

5.  Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses.

Authors:  M Twardziok; D Meierhofer; S Börno; B Timmermann; S Jäger; Sengül Boral; A Eggert; C I Delebinski; G Seifert
Journal:  BMC Complement Altern Med       Date:  2017-04-28       Impact factor: 3.659

6.  Identification of Viscum album L. miRNAs and prediction of their medicinal values.

Authors:  Wenyan Xie; Jacob Adolf; Matthias F Melzig
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240

7.  Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine.

Authors:  Tibor Hajtó; Krisztina Fodor; Pál Perjési; Pèter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-09       Impact factor: 2.629

8.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.

Authors:  K Hostanska; V Vuong; S Rocha; M S Soengas; C Glanzmann; R Saller; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

9.  A Natural Combination Extract of Viscum album L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo.

Authors:  Catharina I Delebinski; Monika Twardziok; Susann Kleinsimon; Florian Hoff; Katharina Mulsow; Jana Rolff; Sebastian Jäger; Angelika Eggert; Georg Seifert
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

10.  A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients.

Authors:  Alessandra Longhi; Marcus Reif; Erminia Mariani; Stefano Ferrari
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-31       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.